$283 Million is the total value of CAXTON CORP's 25 reported holdings in Q2 2018. The portfolio turnover from Q1 2018 to Q2 2018 was 133.3% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
SPY | New | SPDR S&P 500 ETF TRput | $192,636,000 | – | 710,100 | +100.0% | 68.07% | – |
SBBP | Buy | STRONGBRIDGE BIOPHARMA PLC | $32,388,000 | -31.5% | 5,398,034 | +0.4% | 11.44% | -77.7% |
MEIP | New | MEI PHARMA INC | $17,338,000 | – | 4,400,439 | +100.0% | 6.13% | – |
Buy | GARRISON CAP INC | $9,094,000 | +0.4% | 1,118,529 | +0.3% | 3.21% | -67.3% | |
CMFN | Buy | CM FIN INC | $7,905,000 | +19.1% | 888,220 | +9.7% | 2.79% | -61.2% |
MTEM | Buy | MOLECULAR TEMPLATES INC | $5,511,000 | -33.7% | 1,053,787 | +1.4% | 1.95% | -78.4% |
AMLP | New | ALPS ETF TRalerian mlp | $4,233,000 | – | 419,107 | +100.0% | 1.50% | – |
TPIV | New | TAPIMMUNE INC | $798,000 | – | 84,674 | +100.0% | 0.28% | – |
GTXI | Buy | GTX INC DEL | $763,000 | -13.0% | 49,805 | +0.8% | 0.27% | -71.6% |
KURA | New | KURA ONCOLOGY INC | $299,000 | – | 16,415 | +100.0% | 0.11% | – |
Buy | INTEC PHARMA LTD JERUSALEM | $285,000 | -27.8% | 64,817 | +0.8% | 0.10% | -76.5% | |
FPACU | New | FAR PT ACQUISITION CORPunit 06/01/2025 | $225,000 | – | 22,104 | +100.0% | 0.08% | – |
SNSS | New | SUNESIS PHARMACEUTICALS INC | $103,000 | – | 48,707 | +100.0% | 0.04% | – |
ARQL | New | ARQULE INC | $72,000 | – | 12,959 | +100.0% | 0.02% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-08-14
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
MOLECULAR TEMPLATES INC | 24 | Q2 2023 | 30.7% |
STRONGBRIDGE BIOPHARMA PLC | 22 | Q3 2021 | 73.1% |
GARRISON CAP INC | 18 | Q3 2020 | 9.9% |
BERKSHIRE HATHAWAY INC DEL | 17 | Q3 2019 | 5.8% |
EIGER BIOPHARMACEUTICALS INC | 17 | Q3 2022 | 1.7% |
AGILE THERAPEUTICS INC | 16 | Q1 2018 | 55.5% |
KALA PHARNACEUTICALS INC | 16 | Q4 2021 | 17.6% |
CM FIN INC | 16 | Q1 2019 | 7.8% |
SYNTA PHARMACEUTICALS CORP | 15 | Q2 2016 | 99.9% |
CTI BIOPHARMA CORP | 14 | Q4 2021 | 8.7% |
View CAXTON CORP's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Addex Therapeutics Ltd. | February 14, 2023 | 718,849 | 0.9% |
Cardiff Oncology, Inc. | February 14, 2023 | 983,607 | 2.2% |
Rezolute, Inc. | February 14, 2023 | 1,860,518 | 5.0% |
Xeris Biopharma Holdings, Inc. | February 14, 2023 | 5,973,324 | 4.4% |
CTI BIOPHARMA CORP | February 14, 2022 | 2,239,300 | 2.3% |
Sierra Oncology, Inc. | February 14, 2022 | 1,119,322 | 7.0% |
Strongbridge Biopharma plcSold out | January 05, 2022 | 0 | 0.0% |
SUNESIS PHARMACEUTICALS INCSold out | February 16, 2021 | 0 | 0.0% |
Alcentra Capital Corp | February 14, 2020 | 1,005,000 | 7.8% |
Garrison Capital Inc. | February 14, 2020 | 1,223,096 | 7.6% |
View CAXTON CORP's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-05-15 |
13F-HR | 2024-02-14 |
SC 13G/A | 2024-02-13 |
SC 13G/A | 2024-02-13 |
13F-HR | 2023-11-14 |
13F-HR | 2023-08-14 |
13F-HR | 2023-05-15 |
SC 13G/A | 2023-02-14 |
SC 13G/A | 2023-02-14 |
SC 13G/A | 2023-02-14 |
View CAXTON CORP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.